Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
City of Hope Medical Center Identifier:
First received: October 1, 2007
Last updated: February 10, 2016
Last verified: February 2016

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with celecoxib may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying how well giving cyclophosphamide together with celecoxib works compared to cyclophosphamide alone in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Condition Intervention Phase
Fallopian Tube Cancer
Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Drug: cyclophosphamide
Drug: celecoxib
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Pilot Trial of Oral Cyclophosphamide Versus Oral Cyclophosphamide With Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Resource links provided by NLM:

Further study details as provided by City of Hope Medical Center:

Primary Outcome Measures:
  • Response rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Time to disease progression [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Toxicity as assessed by NCI CTC v2.0 [ Time Frame: 4 weeks after end of treatment ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 27
Study Start Date: December 2003
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm I
Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: cyclophosphamide
Given orally
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana
  • Enduxan
Experimental: Arm II
Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: cyclophosphamide
Given orally
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana
  • Enduxan
Drug: celecoxib
Given orally
Other Names:
  • Celebrex
  • SC-58635
  • YM 177

Detailed Description:


I. To assess the response rates in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who are treated with oral cyclophosphamide alone or oral cyclophosphamide with celecoxib.

II. To assess the time to disease progression in this group of patients. III. To further describe the toxicities of oral cyclophosphamide with or without celecoxib in the above patient population.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive oral cyclophosphamide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Patients with recurrent or residual epithelial ovarian, Fallopian tube, or primary papillary peritoneal cancer, which has been histologically confirmed regardless of prior treatment
  • Patients with measurable disease or rising CA-125 to levels at least twice normal (the CA-125 increase must be documented by two independent measurements at least 4 weeks apart)
  • Patient must have adequate renal function documented by a creatinine < 1.5
  • Patients must have adequate bone marrow function as evidenced by an absolute neutrophil count of > 1.5 x 10^9/L and a platelet count > 100 x 10^9/L
  • Patients must have a Karnofsky performance status of 60-100%
  • Patient must be capable of understanding the nature of the trial and must give written informed consent
  • Patients must have life expectancy of at least three months
  • Patients with brain metastases which at the time of study enrollment are controlled and do not require treatment with corticosteroids are eligible


  • Patients who have had radiotherapy or chemotherapy within three weeks prior to anticipated first day of dosing (patients must be fully recovered from the acute effects of any prior chemotherapy or radiotherapy
  • Patient with unstable or severe intercurrent medical conditions or active, uncontrolled infection
  • Patients with history of bleeding peptic ulcer within last 3 months
  • Patients undergoing therapy with other investigational agents (patients must have recovered from all acute effects of previously administered investigational agents and sufficient time must have elapsed since last administration to ensure the drug interactions not occur during this study
  • Patients who are allergic to sulfa drugs
  • Pregnant women will be excluded from this study due to the potential of harm to the fetus
  • Patients with clinically significant cardiovascular disease (e.g. uncontrolled hypertension, myocardial infarction unstable angina), New York heart association grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular disease within 1 year prior to study entry
  • Subjects with hypertension are eligible if their blood pressure as been normal while on a stable dose of medication for at least one year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00538031

United States, California
City of Hope
Duarte, California, United States, 91010
City of Hope Medical Group Inc
Pasadena, California, United States, 91105
Sponsors and Collaborators
City of Hope Medical Center
Principal Investigator: Vincent Chung Beckman Research Institute
  More Information

Responsible Party: City of Hope Medical Center Identifier: NCT00538031     History of Changes
Other Study ID Numbers: 03092  NCI-2009-01597  CDR0000567043 
Study First Received: October 1, 2007
Last Updated: February 10, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Peritoneal Neoplasms
Abdominal Neoplasms
Adnexal Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Peritoneal Diseases
Urogenital Neoplasms
Alkylating Agents
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors processed this record on May 01, 2016